David Moskowitz
Director/Board Member at Cartography Biosciences, Inc.
Profile
David Moskowitz has worked as a Director at Appia Bio, Inc. and currently holds the position of Director at Cartography Biosciences, Inc. Additionally, he is the Principal at Eight Enterprises LLC since 2018.
David Moskowitz active positions
Companies | Position | Start |
---|---|---|
Eight Enterprises LLC
Eight Enterprises LLC Investment ManagersFinance Eight Enterprises LLC (8VC) is a private equity/venture capital firm founded in 2015 by Joseph T. Lonsdale. The firm is headquartered in San Francisco, California. | Private Equity Analyst | 2018-06-30 |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Director/Board Member | - |
Cartography Biosciences, Inc.
Cartography Biosciences, Inc. Pharmaceuticals: OtherHealth Technology Cartography Biosciences, Inc. is a biotech company that specializes in developing tumor-selective therapeutics using a unique genomics and computational platform. The company is based in Foster City, CA. The company integrates data from proprietary sample sourcing relationships, a comprehensive reference atlas, and target identification algorithms to identify the cells of interest and the single or pairs of targets that are most specific to the intended target cells. Cartography Biosciences is unlocking the full potential of immunotherapy by discovering and developing therapeutics as precise as their targets. The company was founded by Ansuman Satpathy, Howard Y. Chang, Kevin Parker. Kevin Parker has been the CEO since incorporation. | Director/Board Member | 2021-10-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Eight Enterprises LLC
Eight Enterprises LLC Investment ManagersFinance Eight Enterprises LLC (8VC) is a private equity/venture capital firm founded in 2015 by Joseph T. Lonsdale. The firm is headquartered in San Francisco, California. | Finance |
Cartography Biosciences, Inc.
Cartography Biosciences, Inc. Pharmaceuticals: OtherHealth Technology Cartography Biosciences, Inc. is a biotech company that specializes in developing tumor-selective therapeutics using a unique genomics and computational platform. The company is based in Foster City, CA. The company integrates data from proprietary sample sourcing relationships, a comprehensive reference atlas, and target identification algorithms to identify the cells of interest and the single or pairs of targets that are most specific to the intended target cells. Cartography Biosciences is unlocking the full potential of immunotherapy by discovering and developing therapeutics as precise as their targets. The company was founded by Ansuman Satpathy, Howard Y. Chang, Kevin Parker. Kevin Parker has been the CEO since incorporation. | Health Technology |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Health Technology |
- Stock Market
- Insiders
- David Moskowitz